ID   RC
AC   CVCL_9U45
DR   ATCC; CRL-3382
DR   Wikidata; Q54949366
RX   PubMed=20664054;
RX   PubMed=26515759;
RX   PubMed=29416618;
RX   PubMed=29666304;
CC   Doubling time: ~4-5 days (PubMed=26515759).
CC   Sequence variation: Gene fusion; HGNC; HGNC:990; BCL2 + HGNC; HGNC:5477; IGH; Name(s)=IGH-BCL2 (PubMed=26515759).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5477; IGH + HGNC; HGNC:7553; MYC; Name(s)=MYC-IGH (PubMed=26515759).
CC   Miscellaneous: STR profile in PubMed=26515759 table 3 is erroneous; correct STR profile obtained by personal communication of Pham, Lan V.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC=CRL-3382; PubMed=26515759
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,11
ST   D16S539: 8,12
ST   D18S51: 17
ST   D21S11: 28,30
ST   D3S1358: 17,19
ST   D5S818: 12,13
ST   D7S820: 10,13
ST   D8S1179: 13,15
ST   FGA: 19,21
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C125904; High grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements
DI   ORDO; Orphanet_480541; High grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 19-12-24; Version: 17
//
RX   PubMed=20664054; DOI=10.1182/blood-2009-12-257378; PMCID=PMC2981542;
RA   Pham L.V., Tamayo A.T., Li C.-P., Bueso-Ramos C.E., Ford R.J. Jr.;
RT   "An epigenetic chromatin remodeling role for NFATc1 in transcriptional
RT   regulation of growth and survival genes in diffuse large B-cell
RT   lymphomas.";
RL   Blood 116:3899-3906(2010).
//
RX   PubMed=26515759; DOI=10.1186/s13045-015-0218-1; PMCID=PMC4627381;
RA   Pham L.V., Lu G., Tamayo A.T., Chen J., Challagundla P.,
RA   Jorgensen J.L., Medeiros L.J., Ford R.J. Jr.;
RT   "Establishment and characterization of a novel MYC/BCL2 'double-hit'
RT   diffuse large B cell lymphoma cell line, RC.";
RL   J. Hematol. Oncol. 8:121.1-121.11(2015).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//